Shared on04 Aug 25Fair value Decreased 7.31%
Vericel’s consensus price target has been revised down from $58.12 to $53.88, primarily due to macro headwinds facing the MedTech sector such as Medicaid cuts, hospital closures, and negative investor sentiment despite some supportive market factors. Analyst Commentary Broad macro pressures, including Medicaid cuts and hospital closures due to recent legislation, are creating headwinds for the MedTech sector and impacting sentiment.
Shared on23 Apr 25Fair value Decreased 0.79%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 2.48%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 0.18%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.